Sections of normal and diseased brain and kidney tissues were screened for the presence of JC virus (JCV) DNA by using the polymerase chain reaction. As expected, all samples obtained from patients with progressive multifocal leukoencephalopathy (PML) tested positive when multiple JCV-specific primer and probe combinations were used. Unexpectedly, more than 50%o of non-PML-affected brains were also found to harbor low levels of JCV DNA. To confirm that the positive signals seen in the tissue sections were not the result of contamination, amplified DNA was cloned and sequenced and in some cases was shown to represent strains of JCV not identified previously. Two predominant regulatory region configurations of JCV have been detected in the human host: archetype JCV, which is excreted in the urine of normal and immunocompromised individuals, and "PML-type" JCV found in diseased brains. This latter group of variants appears to derive from archetype JCV by the deletion and duplication of sequences within the promoter-enhancer region. In the present study, the archetype strain of JCV was identified only in normal kidney samples; JCV DNA found in non-PML-affected brain specimens and in kidney tissue from patients with PML resembled that of strains isolated from PML-affected brain tissue. Our findings indicate that JCV reaches the brain more frequently than previously thought and may persist at this site without causing demyelinating disease. A subsequent episode of prolonged immunodeficiency or a direct interaction with an immunocompromising agent (e.g., human immunodeficiency virus type 1) might activate the latent JCV infection and lead to the development of PML.
JCV not identified previously. Two predominant regulatory region configurations of JCV have been detected in the human host: archetype JCV, which is excreted in the urine of normal and immunocompromised individuals, and "PML-type" JCV found in diseased brains. This latter group of variants appears to derive from archetype JCV by the deletion and duplication of sequences within the promoter-enhancer region. In the present study, the archetype strain of JCV was identified only in normal kidney samples; JCV DNA found in non-PML-affected brain specimens and in kidney tissue from patients with PML resembled that of strains isolated from PML-affected brain tissue. Our findings indicate that JCV reaches the brain more frequently than previously thought and may persist at this site without causing demyelinating disease. A subsequent episode of prolonged immunodeficiency or a direct interaction with an immunocompromising agent (e.g., human immunodeficiency virus type 1) might activate the latent JCV infection and lead to the development of PML.
The polyomavirus JC virus (JCV) infects some 70% of the adult population (53, 63) and is the etiologic agent of progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system (54) . Once considered a rare illness that occurred most frequently in elderly individuals as a terminal complication of lymphoproliferative disease (8) , the incidence of PML has increased dramatically in recent years as a result of the AIDS epidemic (6) . Impairment of immune function by human immunodeficiency virus type 1 (HIV-1) infection contributes to the pathogenesis of PML, but additional factors, such as the ability of the HIV-1 tat protein to activate JCV transcription (62) and the potential for HIV-1 to infect brains which may already harbor JCV (51, 67, 68) , may help explain the relatively high incidence of PML (2 to 7%; 2, 35, 39, 48, 55, 61) in patients with AIDS.
It has been suggested that JCV circulating in the population might persist in the kidney in a form different from that which causes PML (11, 14, 20, 44) . PML is thought to generally arise following reactivation of a persistent kidney infection (reviewed in reference 21). During such an event, alterations to the kidney strain of JCV could generate a variant capable of infecting and lysing oligodendrocytes in the brain. Results from several laboratories support this latter possibility (14, 44, 45) and indicate that one type of JCV, termed archetype (72) , is predominant in the urine of immunocompromised and pregnant individuals (17, 43, 71 by deletions and duplications within the promoter-enhancer region (50, 71) . These variants resemble virus found in PML-affected brain tissue.
JCV DNA has been detected in several organs of patients with PML, including kidney, spleen, and lung (10, 16, 27, 32) . In non-PML-affected patients, the JCV genome has been found in approximately 10% of normal kidney samples (10) and in the urine of immunodeficient individuals (3, 4, 13, 17, 22, 34, 50, 71) . Attempts to uncover JCV in non-PMLaffected brain tissue by using immunofluorescence and DNA hybridization methods have met with little success. These studies have failed to detect JCV in cells cultured from brain tumors (24) or in the brains of patients with schizophrenia (9) or multiple sclerosis (46) . Dorries and coworkers (15) found BK virus (BKV) but not JCV or simian virus 40 (SV40) DNA in human brain tumors when they used specific viral DNA probes. JCV DNA was discovered in biopsy and postmortem samples from the brains of eight patients with neurological diseases, but seven of these showed clinical or laboratory evidence of PML (23) . Recently, Mori et al. (47) found JCV DNA and late proteins in the brain glial cells of 3 of 10 elderly patients (68 to 96 years old) without known neurological disease but not in those of 4 younger individuals (32 to 57 years old). However, conventional histology revealed small demyelinated foci suggestive of subclinical PML in the three elderly patients.
The development of the polymerase chain reaction (PCR) (49, 57) has led to the ability to identify the presence of DNA in tissues at levels previously undetectable. Despite potential problems associated with its high sensitivity (40) , PCR has been successfully applied to the detection and diagnosis of several viral infections involving HIV (38, 52) , human 5726 papillomavirus (60, 66) , and hepatitis B virus (33) . Recently, PCR has been used to detect and characterize JCV DNA in urine (3, 17) and in formalin-fixed, paraffin-embedded PMLaffected brain samples (64) . However, JCV DNA has not been found in either fixed (64) or unfixed (31) specimens of control (non-PML-affected) brain tissue. We now report the detection and characterization of JCV DNA in frozen brain samples from individuals who had not been diagnosed as having PML and who lacked pathological evidence of demyelinating disease.
MATERIALS AND METHODS PCR precautions and optimization. False positives, caused by contamination or by amplification of related sequences, are a well-documented problem of PCR analyses (37, 40) . To reduce the chance of contamination, the following precautions were taken. All reagents were made from fresh stock chemicals and stored in sterile disposable plastic containers. PCR buffer, nucleotides, and primers were prepared in quantity, checked for contamination, and stored in singleuse aliquots. A master mix containing these reagents and Taq polymerase was prepared and aliquoted. Reagents, tissues, and PCR mixture were prepared in laminar-flow hoods or biological safety cabinets in separate rooms. For each set of PCR, multiple negative controls were prepared. These included reactions in which (i) all but one component (e.g., tissue extract, primers, or polymerase) were present in the tube, (ii) BKV or SV40 DNA was used as template, or (iii) extracts of normal hamster brain tissue were tested. Reagents for the negative controls were aliquoted after each set of tissues was prepared, and one such control was used for every six human samples analyzed. Positive controls containing recombinant JCV DNA were prepared only after all tissue sample tubes had been sealed. Separate dedicated sets of positive-displacement pipettors (Gilson, Villiers-leBel, France) were used for preparation of stock reagents and for individual amplification reactions. Microtomes, the thermal cycler, tube racks, and pipettors were cleaned with bleach or 0.1 to 1 M HCl and in some cases subjected to UV illumination between experiments.
To determine whether contamination of tissue samples occurred before the PCR was conducted (65), a set of primers and probe that would identify the recombinant clone, pMadl-TC, was employed (20) . This recombinant clone is the form of JCV DNA used most frequently in our laboratories; pMadl-TC is also the source of a commercial JCV probe used in some diagnostic laboratories. The primer pair (JJP 1 and pJP 2; Table 1 ) amplifies a DNA segment that spans a unique EcoRI site joining the JCV and pBR322 sequences. Amplification of this 313-bp virus-plasmid DNA product from a tissue sample would unequivocally identify JCV contamination from a laboratory source.
To increase the sensitivity and specificity of the PCR, the following criteria were tested and optimized. Sequences of each primer were selected to differentiate between the closely related polyomaviruses, BKV, SV40, and JCV. Pairs of primers were designed to amplify sequences from the early (T-antigen), late (VP1), and regulatory regions of the JCV genome (Table 1 ). The last pair of primers was used in the identification, cloning, and sequencing of variant genomes present in tissue. The ratios and total quantities of the two primers in each pair were optimized to yield the greatest amount of specific product with the least amount of "primerdimer" artifact. Annealing temperatures were selected to ensure specificity of the amplification and discrimination . DNA was UV cross-linked to the filters by using 254-nm germicidal lamps generating a UV dosage of 1.6 kJ/m2 (12) . Filters were prehybridized in 5x Denhardt's solution (20 pug each of bovine serum albumin, Ficoll, and polyvinylpyrrolidone per ml) and 6x SSC at 58°C for at least 1 h. The solution was replaced with a fresh hybridization solution of 5x Denhardt's, 6x SSC, and 0.5% sodium dodecyl sulfate (SDS) containing approximately 300,000 cpm of [32P]ATP-endlabeled oligonucleotide probe (sequences listed in Table 1) for each filter. Hybridization was done at 58°C for a minimum of 5 h. Filters were washed by using the following conditions; 15 min in 2x SSC-1.0% SDS at room temperature, 15 min in lx SSC-1.0% SDS at 58°C, and 15 min in 0.2x SSC-1.0% SDS at 58°C. Filters were exposed on Kodak X-AR film overnight at -70°C with a Dupont Cronex Lightning-Plus intensifying screen.
Recombinant DNA cloning. The cloning vector BSMSKNco was produced by ligating an oligonucleotide adapter (CTAGCCATGG) containing an NcoI restriction site into the Spel site of Bluescript BSMSK.
Following identification of the tissue samples that contained JCV DNA, the remaining portion of the PCR mixture was purified on a Qiagen PCR purification column (Qiagen Inc., Chatsworth, Calif.) according to the manufacturer's suggested protocol. Samples were digested with HindIII (40 U) in buffer containing 50 mM NaCl, 10 mM Tris (pH 7.5), 10 mM MgCl2, and 1 mM dithiothreitol for a minimum of 2 h at 37°C. The NaCl concentration was adjusted to 100 mM, and the samples were digested with NcoI (30 U) for an additional 2 h. The restriction endonucleases were heat inactivated at 56°C for 15 min, and the reaction mixture was desalted by using a Sephadex G-50 spin column equilibrated in TE ( Extensive precautions (detailed in Materials and Methods) were taken to reduce the possibility of contamination during tissue or reagent preparation. In the unusual event (<5%) that a negative control in a given set of reactions produced a positive signal for the viral DNA being tested, all results for that experiment were disregarded. As an additional negative control, sections of normal hamster brain were cut before and after the human brain samples were cut. This was done to examine the possibility of carryover contamination via the cryostat during the sectioning. These hamster brain sections were consistently negative for JCV DNA.
Samples of PML-affected brain tissue were the first to be tested for the presence of JCV DNA. As expected, the specific early-, late-, and regulatory-region primers amplified JCV DNA in all seven specimens (100%; Table 3 ). An autoradiogram representative of these results is shown in Fig. 1 .
The results of the experiments with non-PML-affected brain samples are summarized in Table 3 , and representative autoradiograms are shown in Fig. 2 . When tested with primers and probes specific for the different regions of the JCV genome, tissue sections from 15 (68%) of 22 non-PMLaffected brains were positive two or more times for JCV DNA. Unlike the PML-affected brain samples, however, not all sections of non-PML-affected brains gave a positive signal. Furthermore, the intensity of their signals was significantly less than that observed with the PML-affected tissues (compare Fig. 1 and 2) .
The JCV DNA clone pMadl-TC is used routinely in our laboratories and represents a potential source of contamination during tissue handling. To In addition to brain tissue samples, kidney tissues from PML-and non-PML-affected patients were also tested. Using the same combinations of primers and probes, JCV DNA was detected in 5 (100%) of 5 kidneys from patients with PML and in 7 (50%) of 14 kidneys from patients without PML ( Fig. 1; Table 3 ). Again, more variability was seen with non-PML-affected samples; not all sections gave a positive signal, and fewer copies of the JCV genome were present.
While stringent measures were taken to avoid contamination, we reasoned that the presence of JCV in non-PMLaffected brain would be demonstrated most convincingly by the cloning and sequencing of the DNA from several positive samples and confirming that at least some of these strains (Fig. 3) . The two sets of clones differed from one another at four nucleotide positions; two of these positions have been identified as hot spots of variation in the archetype regulatory region (72 In the sequence of a clone derived from the kidney of a PML patient (PO/PK), a single nucleotide, which is not found in the archetype sequence, immediately follows position 114 of each repeat (C after repeat 1 and A after repeat 2). The following abbreviations were used to designate the sources of the isolates: PB and PK for brain and kidney, respectively, from patients with PML; NB and NK for brain and kidney, respectively, from patients without PML. This figure was adapted from one by Yogo et al. (72) .
(Dun) regulatory region (59) . The regulatory regions of the kidney and brain variants of JCV in patient GU differ but are clearly related. Both have the characteristic deletion and amplification of promoter-enhancer sequences seen in PMLaffected brain isolates. This is the first time two different "PML-type" clones have been identified directly in the tissues of a single individual. There has been one other report of isolating JCV from both the brain (GS/B) and kidney (GS/K) of a single patient with PML (41) , but in that case, a strain resembling archetype JCV was identified in the kidney.
To check the fidelity of the PCR amplification, brain tissue samples from which JCV(Mad8Br) was originally isolated were obtained (26) . Following amplification with JRR 1 and 2, multiple clones were derived; their sequences precisely matched that previously published for JCV(Mad8Br) (Fig.   3 ).
Twenty-one normal and PML-affected brain specimens were also examined by using BKV-specific primers and probes that were known to amplify sequences from five BKV variants [BKV(AS), BKV9, BKV(Dun), BKV(WT), and BKV(DB); data not shown]. Only one non-PML-affected brain sample in one experiment gave a positive signal following Southern blotting and hybridization with a BKVspecific oligonucleotide probe (data not shown). Three additional experiments failed to repeat this result.
The brain tissue samples which showed evidence by PCR of JCV infection ( (14, 27, 32) . While similar studies with non-PML-affected patients have not been as extensive, there is ample evidence that JCV persists in the kidneys of many of these individuals (10) and is occasionally released into their urine (3, 17, 34, 43, 50, 71, 72) . A number of groups have also looked for JCV in the brains of non-PML-affected individuals (9, 10, 15, 31, 46, 64) (Fig. 3) , a sequence which shares homology with a negative regulatory element in BKV (25) .
Transport of JCV to the brain presumably occurs via a hematogenous route, and the detection of JCV DNA and proteins in B lymphocytes of the bone marrow (32) supports this concept. This does, however, raise the possibility that the positive signals seen in non-PML-affected brain samples are due to the presence of infected lymphocytes in the lumina of cerebral vessels or of free virus in the circulation at the time of death. Although our data do not rule out this possibility, two lines of evidence argue against it. First, since BKV, like JCV, can reactivate in the kidney under conditions of immunosuppression, it also might appear in the circulation around the time of death. Thus, detection of BKV DNA in the circulation, and therefore apparently in the brain samples, might be expected as well. Yet, of 21 brain sections tested, only 1 exhibited a positive signal for BKV; additional experiments have failed to repeat even this result. Second, the failure to identify JCV archetype in brain tissue rules out the presence of normal kidney-type virus in vessels in these samples (as well as ruling out contamination of our samples by urinary virus acquired during handling) as an explanation of these results. We interpret these data to indicate that JCV is present within the brains of non-PMLaffected patients and is not merely a passenger of circulating lymphocytes in the plasma.
If the JCV DNA sequences we have detected in brains without known neurological disease truly represent a latent infection, one would not expect to find viral proteins or replicating viral DNA in the samples. We therefore tested the tissues containing JCV DNA sequences for the presence of the early protein, T antigen, by using a sensitive immunocytochemical method capable of detecting T antigen in vascular endothelial cells of JCV-infected hamster brain tissue (56) . We also conducted in situ hybridization techniques which can detect replicating JCV DNA in glial cells of patients with PML (1, 32) . Both approaches yielded negative results. These findings are consistent with a latent infection which remains quiescent even in aged individuals such as patients AE, RA, and 884. The unexpected findings reported in this study may be especially relevant to our understanding of the pathogenesis of PML in patients with AIDS. Although PML was once considered a rare disease, its incidence has increased dramatically because of the AIDS epidemic (6) . This increase may not be due simply to the immunosuppressive effects of an HIV-1 infection; there is evidence in vitro that the HIV tat protein can transactivate JCV transcription (62) . Given that JCV may reside in the non-PML-affected brain (this study) and that HIV-1 infection involves the central nervous system in a high proportion of patients with AIDS (36, 69, 70) , it is possible that HIV-1 can reactivate a latent JCV infection, thereby increasing the risk of clinical PML. Alternatively, should reactivation occur prior to entry of HIV-1 into the brain, replication of JCV might lead to the recruitment of HIV-1-infected macrophages and lymphocytes to this site, thereby potentiating the spread of infection (67, 68) . In either case, the presence of this opportunistic pathogen in many normal brains may have untoward consequences for an individual should that person experience a severe immunocompromising event such as a superinfection with an activating retrovirus.
ACKNOWLEDGMENTS
We thank Carla Myers for assistance in setting up the PCR in the laboratory and Caroline Ryschkewitsch for expert technical assistance. Tissue specimens used in this study were obtained from the MS Human Neurospecimen Bank, VAMC Wadsworth Division, Los Angeles, Calif., which is sponsored by NMSS, NINDS/NIMH, HD Foundation, and Veterans Administration, and from the Rocky Mountain MS Center.
